Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game
Aliment Pharmacol Ther
.
2022 Jul;56(2):353-354.
doi: 10.1111/apt.17044.
Authors
Madeleine Gill
1
2
3
,
Avik Majumdar
1
2
4
5
Affiliations
1
AW Morrow Gastroenterology and Liver Unit, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
2
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
3
Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, New South Wales, Australia.
4
Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia.
5
The University of Melbourne, Melbourne, Victoria, Australia.
PMID:
35748830
DOI:
10.1111/apt.17044
No abstract available
Publication types
Editorial
Comment
MeSH terms
Hepatitis B Antibodies
Hepatitis B Vaccines*
Humans
Inflammatory Bowel Diseases*
Substances
Hepatitis B Antibodies
Hepatitis B Vaccines